Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Innovations in addressing pediatric diarrhea in low resource settings.

Jumani RS, Spector JM, Izadnegahdar R, Kelly P, Diagana TT, Manjunatha UH.

ACS Infect Dis. 2019 Oct 15. doi: 10.1021/acsinfecdis.9b00315. [Epub ahead of print]

PMID:
31612701
2.

Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages.

Chua ACY, Ong JJY, Malleret B, Suwanarusk R, Kosaisavee V, Zeeman AM, Cooper CA, Tan KSW, Zhang R, Tan BH, Abas SN, Yip A, Elliot A, Joyner CJ, Cho JS, Breyer K, Baran S, Lange A, Maher SP, Nosten F, Bodenreider C, Yeung BKS, Mazier D, Galinski MR, Dereuddre-Bosquet N, Le Grand R, Kocken CHM, Rénia L, Kyle DE, Diagana TT, Snounou G, Russell B, Bifani P.

Nat Commun. 2019 Aug 12;10(1):3635. doi: 10.1038/s41467-019-11332-4.

3.

Hepatic spheroids used as an in vitro model to study malaria relapse.

Chua ACY, Ananthanarayanan A, Ong JJY, Wong JY, Yip A, Singh NH, Qu Y, Dembele L, McMillian M, Ubalee R, Davidson S, Tungtaeng A, Imerbsin R, Gupta K, Andolina C, Lee F, S-W Tan K, Nosten F, Russell B, Lange A, Diagana TT, Rénia L, Yeung BKS, Yu H, Bifani P.

Biomaterials. 2019 Sep;216:119221. doi: 10.1016/j.biomaterials.2019.05.032. Epub 2019 May 22.

4.

The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development.

Gupta DK, Dembele L, Voorberg-van der Wel A, Roma G, Yip A, Chuenchob V, Kangwanrangsan N, Ishino T, Vaughan AM, Kappe SH, Flannery EL, Sattabongkot J, Mikolajczak S, Bifani P, Kocken CH, Diagana TT.

Elife. 2019 May 16;8. pii: e43362. doi: 10.7554/eLife.43362.

5.

Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy.

Bertschi NL, Voorberg-van der Wel A, Zeeman AM, Schuierer S, Nigsch F, Carbone W, Knehr J, Gupta DK, Hofman SO, van der Werff N, Nieuwenhuis I, Klooster E, Faber BW, Flannery EL, Mikolajczak SA, Chuenchob V, Shrestha B, Beibel M, Bouwmeester T, Kangwanrangsan N, Sattabongkot J, Diagana TT, Kocken CH, Roma G.

Elife. 2018 Dec 27;7. pii: e41081. doi: 10.7554/eLife.41081.

6.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Rao SPS, Barrett MP, Dranoff G, Faraday CJ, Gimpelewicz CR, Hailu A, Jones CL, Kelly JM, Lazdins-Helds JK, Mäser P, Mengel J, Mottram JC, Mowbray CE, Sacks DL, Scott P, Späth GF, Tarleton RL, Spector JM, Diagana TT.

ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.

7.

Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro.

Dembele L, Gupta DK, Lim MY, Ang X, Selva JJ, Chotivanich K, Nguon C, Dondorp AM, Bonamy GMC, Diagana TT, Bifani P.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02235-17. doi: 10.1128/AAC.02235-17. Print 2018 May.

8.

Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium.

Chao AT, Lee BH, Wan KF, Selva J, Zou B, Gedeck P, Beer DJ, Diagana TT, Bonamy GMC, Manjunatha UH.

ACS Infect Dis. 2018 Apr 13;4(4):635-645. doi: 10.1021/acsinfecdis.7b00247. Epub 2018 Jan 25.

PMID:
29341586
9.

A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi.

Voorberg-van der Wel A, Roma G, Gupta DK, Schuierer S, Nigsch F, Carbone W, Zeeman AM, Lee BH, Hofman SO, Faber BW, Knehr J, Pasini E, Kinzel B, Bifani P, Bonamy GMC, Bouwmeester T, Kocken CHM, Diagana TT.

Elife. 2017 Dec 7;6. pii: e29605. doi: 10.7554/eLife.29605.

10.

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.

Manjunatha UH, Vinayak S, Zambriski JA, Chao AT, Sy T, Noble CG, Bonamy GMC, Kondreddi RR, Zou B, Gedeck P, Brooks CF, Herbert GT, Sateriale A, Tandel J, Noh S, Lakshminarayana SB, Lim SH, Goodman LB, Bodenreider C, Feng G, Zhang L, Blasco F, Wagner J, Leong FJ, Striepen B, Diagana TT.

Nature. 2017 Jun 15;546(7658):376-380. doi: 10.1038/nature22337. Epub 2017 May 31.

11.

The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.

Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P.

Sci Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6.

12.

Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.

White NJ, Duong TT, Uthaisin C, Nosten F, Phyo AP, Hanboonkunupakarn B, Pukrittayakamee S, Jittamala P, Chuthasmit K, Cheung MS, Feng Y, Li R, Magnusson B, Sultan M, Wieser D, Xun X, Zhao R, Diagana TT, Pertel P, Leong FJ.

N Engl J Med. 2016 Sep 22;375(12):1152-60. doi: 10.1056/NEJMoa1602250.

13.

UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes.

Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P.

Nat Microbiol. 2016 Sep 19;1:16166. doi: 10.1038/nmicrobiol.2016.166.

14.

Cryptosporidiosis Drug Discovery: Opportunities and Challenges.

Manjunatha UH, Chao AT, Leong FJ, Diagana TT.

ACS Infect Dis. 2016 Aug 12;2(8):530-7. doi: 10.1021/acsinfecdis.6b00094. Epub 2016 Jul 22. Review.

PMID:
27626293
15.

The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites.

Chavchich M, Van Breda K, Rowcliffe K, Diagana TT, Edstein MD.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5167-74. doi: 10.1128/AAC.02838-15. Print 2016 Sep.

16.

PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites.

Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der Wel A, Kondreddi RR, Bodenreider C, Simon O, Sauerwein R, Yeung BK, Diagana TT, Kocken CH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63. doi: 10.1128/AAC.03080-15. Print 2016 May.

17.

Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.

Ng PS, Manjunatha UH, Rao SP, Camacho LR, Ma NL, Herve M, Noble CG, Goh A, Peukert S, Diagana TT, Smith PW, Kondreddi RR.

Eur J Med Chem. 2015 Dec 1;106:144-56. doi: 10.1016/j.ejmech.2015.10.008. Epub 2015 Oct 14.

PMID:
26544629
18.

Supporting malaria elimination with 21st century antimalarial agent drug discovery.

Diagana TT.

Drug Discov Today. 2015 Oct;20(10):1265-70. doi: 10.1016/j.drudis.2015.06.009. Epub 2015 Jun 21. Review.

19.

Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases.

Jones CL, Yeung BK, Manjunatha U, Shi PY, Bodenreider C, Diagana TT.

Nat Rev Drug Discov. 2015 Jun;14(6):442-4. doi: 10.1038/nrd4001-c1. No abstract available.

PMID:
26027536
20.

Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors.

Zou B, Chan WL, Ding M, Leong SY, Nilar S, Seah PG, Liu W, Karuna R, Blasco F, Yip A, Chao A, Susila A, Dong H, Wang QY, Xu HY, Chan K, Wan KF, Gu F, Diagana TT, Wagner T, Dix I, Shi PY, Smith PW.

ACS Med Chem Lett. 2015 Feb 2;6(3):344-8. doi: 10.1021/ml500521r. eCollection 2015 Mar 12.

21.

Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Manjunatha UH, S Rao SP, Kondreddi RR, Noble CG, Camacho LR, Tan BH, Ng SH, Ng PS, Ma NL, Lakshminarayana SB, Herve M, Barnes SW, Yu W, Kuhen K, Blasco F, Beer D, Walker JR, Tonge PJ, Glynne R, Smith PW, Diagana TT.

Sci Transl Med. 2015 Jan 7;7(269):269ra3. doi: 10.1126/scitranslmed.3010597.

22.

Therapeutics for Neglected Infectious Diseases: Progress and Challenge.

Shi PY, Smith PW, Diagana TT.

ACS Infect Dis. 2015 Jan 9;1(1):76-8. doi: 10.1021/id500043r. No abstract available.

PMID:
27620147
23.

Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.

Lakshminarayana SB, Freymond C, Fischli C, Yu J, Weber S, Goh A, Yeung BK, Ho PC, Dartois V, Diagana TT, Rottmann M, Blasco F.

Antimicrob Agents Chemother. 2015 Feb;59(2):1200-10. doi: 10.1128/AAC.03274-14. Epub 2014 Dec 8.

24.

Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages.

Zou B, Nagle A, Chatterjee AK, Leong SY, Tan LJ, Sim WL, Mishra P, Guntapalli P, Tully DC, Lakshminarayana SB, Lim CS, Tan YC, Abas SN, Bodenreider C, Kuhen KL, Gagaring K, Borboa R, Chang J, Li C, Hollenbeck T, Tuntland T, Zeeman AM, Kocken CH, McNamara C, Kato N, Winzeler EA, Yeung BK, Diagana TT, Smith PW, Roland J.

ACS Med Chem Lett. 2014 Jul 6;5(8):947-50. doi: 10.1021/ml500244m. eCollection 2014 Aug 14.

25.
26.
27.

Spiroindolone KAE609 for falciparum and vivax malaria.

White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefèvre G, Li R, Magnusson B, Diagana TT, Leong FJ.

N Engl J Med. 2014 Jul 31;371(5):403-10. doi: 10.1056/NEJMoa1315860.

28.

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT.

Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.

29.

Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures.

Dembélé L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, Le Grand R, Dereuddre-Bosquet N, van Gemert GJ, Sauerwein R, Vaillant JC, Hannoun L, Fuchter MJ, Diagana TT, Malmquist NA, Scherf A, Snounou G, Mazier D.

Nat Med. 2014 Mar;20(3):307-12. doi: 10.1038/nm.3461. Epub 2014 Feb 9.

PMID:
24509527
30.

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Zeeman AM, van Amsterdam SM, McNamara CW, Voorberg-van der Wel A, Klooster EJ, van den Berg A, Remarque EJ, Plouffe DM, van Gemert GJ, Luty A, Sauerwein R, Gagaring K, Borboa R, Chen Z, Kuhen K, Glynne RJ, Chatterjee AK, Nagle A, Roland J, Winzeler EA, Leroy D, Campo B, Diagana TT, Yeung BK, Thomas AW, Kocken CH.

Antimicrob Agents Chemother. 2014;58(3):1586-95. doi: 10.1128/AAC.01927-13. Epub 2013 Dec 23.

31.

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH.

Sci Transl Med. 2013 Dec 4;5(214):214ra168. doi: 10.1126/scitranslmed.3007355.

32.

Targeting Plasmodium PI(4)K to eliminate malaria.

McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Nagle A, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA.

Nature. 2013 Dec 12;504(7479):248-253. doi: 10.1038/nature12782. Epub 2013 Nov 27.

33.

Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.

Kondreddi RR, Jiricek J, Rao SP, Lakshminarayana SB, Camacho LR, Rao R, Herve M, Bifani P, Ma NL, Kuhen K, Goh A, Chatterjee AK, Dick T, Diagana TT, Manjunatha UH, Smith PW.

J Med Chem. 2013 Nov 14;56(21):8849-59. doi: 10.1021/jm4012774. Epub 2013 Oct 22.

PMID:
24090347
34.

Progressing the global antimalarial portfolio: finding drugs which target multiple Plasmodium life stages.

Smith PW, Diagana TT, Yeung BK.

Parasitology. 2014 Jan;141(1):66-76. doi: 10.1017/S0031182013000747. Epub 2013 Jun 10. Review.

PMID:
23746048
35.

Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.

Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K.

Cell Host Microbe. 2013 Feb 13;13(2):227-37. doi: 10.1016/j.chom.2012.12.006.

36.

Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.

Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, Ballard J, Supek F, Golde TE, Winzeler EA, Diagana TT, Greenbaum DC.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21486-91. doi: 10.1073/pnas.1216016110. Epub 2012 Dec 11.

37.

Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin.

Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, Aust T, McCormack SL, Plouffe DM, Meister S, Schuierer S, Plikat U, Hartmann N, Staedtler F, Cotesta S, Schmitt EK, Petersen F, Supek F, Glynne RJ, Tallarico JA, Porter JA, Fishman MC, Bodenreider C, Diagana TT, Movva NR, Winzeler EA.

Cell Host Microbe. 2012 Jun 14;11(6):654-63. doi: 10.1016/j.chom.2012.04.015.

38.

Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.

Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK.

J Med Chem. 2012 May 10;55(9):4244-73. doi: 10.1021/jm300041e. Epub 2012 Apr 23.

39.

The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.

van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M, van Gemert GJ, Rottmann M, Yeung BK, Diagana TT, Sauerwein RW.

Antimicrob Agents Chemother. 2012 Jul;56(7):3544-8. doi: 10.1128/AAC.06377-11. Epub 2012 Apr 16.

40.

Global phenotypic screening for antimalarials.

Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK.

Chem Biol. 2012 Jan 27;19(1):116-29. doi: 10.1016/j.chembiol.2012.01.004. Review.

41.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

42.

Spiroindolones, a potent compound class for the treatment of malaria.

Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT.

Science. 2010 Sep 3;329(5996):1175-80. doi: 10.1126/science.1193225.

43.

Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.

Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH.

J Med Chem. 2010 Jul 22;53(14):5155-64. doi: 10.1021/jm100410f.

PMID:
20568778
44.

Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.

Nzila A, Rottmann M, Chitnumsub P, Kiara SM, Kamchonwongpaisan S, Maneeruttanarungroj C, Taweechai S, Yeung BK, Goh A, Lakshminarayana SB, Zou B, Wong J, Ma NL, Weaver M, Keller TH, Dartois V, Wittlin S, Brun R, Yuthavong Y, Diagana TT.

Antimicrob Agents Chemother. 2010 Jun;54(6):2603-10. doi: 10.1128/AAC.01526-09. Epub 2010 Mar 29.

45.

Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs.

Hale V, Keasling JD, Renninger N, Diagana TT.

Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):198-202. Review.

PMID:
18165493
46.

Mutation of Drosophila homer disrupts control of locomotor activity and behavioral plasticity.

Diagana TT, Thomas U, Prokopenko SN, Xiao B, Worley PF, Thomas JB.

J Neurosci. 2002 Jan 15;22(2):428-36.

47.
49.

The transcriptional activity of a muscle-specific promoter depends critically on the structure of the TATA element and its binding protein.

Diagana TT, North DL, Jabet C, Fiszman MY, Takeda S, Whalen RG.

J Mol Biol. 1997 Feb 7;265(5):480-93.

PMID:
9048943

Supplemental Content

Loading ...
Support Center